Bristol Myers Squibb (BMY) Amortization - Intangibles (2019 - 2026)

Bristol Myers Squibb has disclosed Amortization - Intangibles across 8 years of filings, most recently posting $437.0 million for Q1 2026.

• In Q1 2026, Amortization - Intangibles fell 47.35% year-over-year to $437.0 million; the TTM figure through Mar 2026 stood at $2.9 billion (down 60.19% YoY), while the FY2025 annual figure was $3.3 billion, down 62.61% from the prior year.
• Amortization - Intangibles fell to $437.0 million in Q1 2026, from $826.0 million in the prior quarter.
• Over the last five years, Amortization - Intangibles for BMY reached as high as $2.4 billion in Q3 2022 and fell as low as $437.0 million in Q1 2026.
• The 5-year median for Amortization - Intangibles is $2.3 billion (2023), against an average of $1.8 billion.
• Annual changes were most pronounced in 2024 — Amortization - Intangibles rose 7.04% — and 2025, when it plunged 65.65%.
• A 5-year view of Amortization - Intangibles shows it stood at $2.3 billion in 2022, then dropped by 2.77% to $2.3 billion in 2023, then slipped by 25.68% to $1.7 billion in 2024, then slumped by 51.21% to $826.0 million in 2025, then slumped by 47.09% to $437.0 million in 2026.
• According to Business Quant data, Amortization - Intangibles over the past three periods registered $437.0 million, $826.0 million, and $831.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.